RNA-based therapies targeting APOC3 lower triglyceride levels in patients with hypertriglyceridaemia
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Among patients with hypertriglyceridemia and mixed dyslipidemia, siRNA therapies targeting APOC3 and ANGPTL3 have demonstrated favorable effects on non-HDL-C, apoB, and VLDL-C across phase I-III clinical trials.
“Among patients with HTG and mixed dyslipidemia, siRNA therapies targeting APOC3 and ANGPTL3 have demonstrated marked TG reductions and favorable effects on non–HDL-C, apoB, and very-low-density lipoprotein cholesterol (VLDL-C) across phase I–III clinical trials (Gaudet et al., 2024; Huynh, 2024; Ray et al., 2025; Bornfeldt, 2024; Schwabe et al., 2020; Lim, 2024).”
From Efficacy and safety of small interfering RNA (siRNA) therapies for hypertriglyceridemia and mixed dyslipidemia: an updated systematic review and meta-analysis (2026) · cites this paper as Huynh, 2024
Among patients with hypertriglyceridemia and mixed dyslipidemia, siRNA therapies targeting APOC3 and ANGPTL3 have demonstrated marked triglyceride reductions across phase I-III clinical trials.
“Among patients with HTG and mixed dyslipidemia, siRNA therapies targeting APOC3 and ANGPTL3 have demonstrated marked TG reductions and favorable effects on non–HDL-C, apoB, and very-low-density lipoprotein cholesterol (VLDL-C) across phase I–III clinical trials (Gaudet et al., 2024; Huynh, 2024; Ray et al., 2025; Bornfeldt, 2024; Schwabe et al., 2020; Lim, 2024).”
From Efficacy and safety of small interfering RNA (siRNA) therapies for hypertriglyceridemia and mixed dyslipidemia: an updated systematic review and meta-analysis (2026) · cites this paper as Huynh, 2024
Cites
Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome
Stroes, E. S. G., Alexander, V. J., Karwatowska-Prokopczuk, E., Hegele, R. A., Arca, M., Ballantyne, C. M., Soran, H., Prohaska, T. A., Xia, S., Ginsberg, H. N., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2400201 · Cited by 271 · see citing works
Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk
Bergmark, B. A., Marston, N. A., Prohaska, T. A., Alexander, V. J., Zimerman, A., Moura, F. A., Murphy, S. A., Goodrich, E. L., Zhang, S., Gaudet, D., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2402309 · Cited by 198 · see citing works
Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia
Gaudet, D., Pall, D., Watts, G. F., Nicholls, S. J., Rosenson, R. S., Modesto, K., San Martin, J., Hellawell, J., & Ballantyne, C. M. (2024) · JAMA Cardiology · doi:10.1001/jamacardio.2024.0959 · Cited by 172 · see citing works
Novel and future lipid-modulating therapies for the prevention of cardiovascular disease
Brandts, J., & Ray, K. K. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00860-8 · Cited by 107 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Tian, Z., Luo, H., Chu, Y., Liu, Y., Gao, S., Song, L., Yang, Z., & Liu, D. (2025) · Clinical Pharmacokinetics · doi:10.1007/s40262-025-01513-4 · Cited by 6 · see citing works
Gao, Y., Bai, Y., Mu, X., & Pang, X. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1736821 · Cited by 4 · see citing works
“…APOC3 and ANGPTL3 have demonstrated marked TG reductions and favorable effects on non–HDL-C, apoB, and very-low-density lipoprotein cholesterol (VLDL-C) across phase I–III clinical trials (Gaudet et al., 2024; Huynh, 2024; Ray et al., 2025; Bornfeldt, 2024; Schwabe et al., 2020; Lim, 2024).”
Zheng, M., Zuo, J., Zhou, B., Hong, T., Yang, Y., Jiang, Z., Ni, H., & Ou, Y. (2026) · Food Bioscience · doi:10.1016/j.fbio.2026.109117
- Authors
- Huynh, K.
- Corresponding author
- Huynh, Karina
- Venue
- Nature Reviews Cardiology
- Published
- 2024-04-23
- Volume
- 21
- Issue
- 6
- Pages
- 353-353
- ISSN
- 1759-5002 (ISSN-L)
- 1759-5010
- OpenAlex
- W4395030209
- Cited by
- 3
- References
- 4
- Citations by year
- 2026: 2 · 2025: 1
- FWCI
- 0.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Nature Reviews Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- apolipoprotein C-III, RNA therapeutics, olezarsen, plozasiran, hypertriglyceridemia, triglyceride lowering, antisense oligonucleotides, randomized controlled trials
- MeSH terms
- Humans, Triglycerides, Hypertriglyceridemia, Apolipoprotein C-III
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
